Thomas E. Witzig
Impact in
- Hematology top 0.02%
- Multiple Myeloma Research and Treatments
- Pathology and Forensic Medicine top 0.01%
- Lymphoma Diagnosis and Treatment
Papers in
-
- Lymphoma Diagnosis and Treatment 424
- Genetics 261
- Chronic Lymphocytic Leukemia Research 236
- Co-authors
- Philip R. Greipp (108 shared papers)S. Vincent Rajkumar (111 shared papers)Robert A. Kyle (89 shared papers)Stephen M. Ansell (236 shared papers)Martha Q. Lacy (107 shared papers)Morie A. Gertz (113 shared papers)John A. Lust (86 shared papers)Angela Dispenzieri (97 shared papers)
- Journals
- Blood (250 papers)Journal of Clinical Oncology (109 papers)American Journal of Hematology (41 papers)British Journal of Haematology (27 papers)Blood Cancer Journal (23 papers)
- Partner nations
- United StatesItalyCanada
In The Last Decade
Thomas E. Witzig
752 papers receiving 34.8k citations
Thomas E. Witzig's Hit Papers
Peers
Comparison fields: 5 of 164
- Hematology 9.4k
- Pathology and Forensic Medicine 13.0k
- Genetics 7.8k
- Oncology 11.6k
- Immunology 5.4k
Countries citing papers authored by Thomas E. Witzig
This map shows the geographic impact of Thomas E. Witzig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Witzig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Witzig more than expected).
Fields of papers citing papers by Thomas E. Witzig
This network shows the impact of papers produced by Thomas E. Witzig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Witzig. The network helps show where Thomas E. Witzig may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas E. Witzig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 786 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Review of 1027 Patients With Newly Diagnosed Multiple Myeloma Hit paper breakdown → | 2003 | 1734 |
| 2 | Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma Hit paper breakdown → | 2002 | 913 |
| 3 | Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis Hit paper breakdown → | 2004 | 671 |
| 4 | POEMS syndrome: definitions and long-term outcome Hit paper breakdown → | 2003 | 553 |
| 5 | A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and Colchicine Hit paper breakdown → | 1997 | 517 |
| 6 | Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma Hit paper breakdown → | 2002 | 513 |
| 7 | Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma Hit paper breakdown → | 2005 | 501 |
| 8 | Rituximab for IgG4-related disease: a prospective, open-label trial Hit paper breakdown → | 2015 | 480 |
| 9 | 1999 | 453 | |
| 10 | 2002 | 424 | |
| 11 | 2005 | 422 | |
| 12 | 2006 | 361 | |
| 13 | 2011 | 309 | |
| 14 | 2013 | 278 | |
| 15 | 2012 | 276 | |
| 16 | 2004 | 275 | |
| 17 | Prognostic value of bone marrow angiogenesis in multiple myeloma. | 2000 | 275 |
| 18 | 2014 | 273 | |
| 19 | 2010 | 258 | |
| 20 | 2009 | 257 |
About Thomas E. Witzig
Thomas E. Witzig is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Molecular Biology and Hematology, having authored 786 papers that have together received 36.1k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (424 papers), Chronic Lymphocytic Leukemia Research (236 papers), Multiple Myeloma Research and Treatments (131 papers), Viral-associated cancers and disorders (75 papers), Monoclonal and Polyclonal Antibodies Research (51 papers), CNS Lymphoma Diagnosis and Treatment (43 papers), CAR-T cell therapy research (42 papers) and Immune Cell Function and Interaction (41 papers). The work is most often cited by research in Hematology (9.4k citations), Pathology and Forensic Medicine (13.0k citations), Genetics (7.8k citations), Oncology (11.6k citations) and Immunology (5.4k citations). Thomas E. Witzig has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Philip R. Greipp, S. Vincent Rajkumar, Robert A. Kyle, Stephen M. Ansell, Martha Q. Lacy, Morie A. Gertz, John A. Lust, Angela Dispenzieri, Rafaël Fonseca and Thomas M. Habermann. Their work appears in journals such as Blood, Journal of Clinical Oncology, American Journal of Hematology, British Journal of Haematology and Blood Cancer Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.